GSK Shoots For Next Growth Phase In India With Bigger Push Into Vaccines, Pharma And Consumer Health
This article was originally published in PharmAsia News
Executive Summary
For the first time, the global board of directors of the British pharma and consumer healthcare giant met in India, and a series of moves to power further growth could be on the way.
You may also be interested in...
GSK CEO Calls For Change In Business Model As World Power Moves To Emerging Economies
MUMBAI - Fifty years from now, the period between 2005 and 2020 may be seen as critical years of change when the world witnessed a fundamental shift in economic power from a model dominated for the last 250 years to an evolutionary one led by emerging markets rather than Western economies
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?
MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets